PT - JOURNAL ARTICLE AU - Neil R. Aggarwal AU - Laurel E. Beaty AU - Tellen D. Bennett AU - Nichole E. Carlson AU - Christopher B. Davis AU - Bethany M. Kwan AU - David A. Mayer AU - Toan C. Ong AU - Seth Russell AU - Jeffrey Steele AU - Adane F. Wogu AU - Matthew K. Wynia AU - Richard D. Zane AU - Adit A. Ginde TI - Real World Evidence of the Neutralizing Monoclonal Antibody Sotrovimab for Preventing Hospitalization and Mortality in COVID-19 Outpatients AID - 10.1101/2022.04.03.22273360 DP - 2022 Jan 01 TA - medRxiv PG - 2022.04.03.22273360 4099 - http://medrxiv.org/content/early/2022/04/05/2022.04.03.22273360.short 4100 - http://medrxiv.org/content/early/2022/04/05/2022.04.03.22273360.full AB - Background It is not known whether sotrovimab, a neutralizing monoclonal antibody (mAb) treatment authorized for early symptomatic COVID-19 patients, is effective against the SARS-CoV-2 Delta variant to prevent progression to severe disease and mortality.Methods Observational cohort study of non-hospitalized adult patients with SARS-CoV-2 infection from October 1st 2021 - December 11th 2021, using electronic health records from a statewide health system plus state-level vaccine and mortality data. We used propensity matching to select 3 patients not receiving mAbs for each patient who received outpatient sotrovimab treatment. The primary outcome was 28-day hospitalization; secondary outcomes included mortality and severity of hospitalization.Results Of 10,036 patients with SARS-CoV-2 infection, 522 receiving sotrovimab were matched to 1,563 not receiving mAbs. Compared to mAb-untreated patients, sotrovimab treatment was associated with a 63% decrease in the odds of all-cause hospitalization (raw rate 2.1% versus 5.7%; adjusted OR 0.37, 95% CI 0.19-0.66) and an 89% decrease in the odds of all-cause 28-day mortality (raw rate 0% versus 1.0%; adjusted OR 0.11, 95% CI 0.0-0.79), and may reduce respiratory disease severity among those hospitalized.Conclusion Real-world evidence demonstrated sotrovimab effectiveness in reducing hospitalization and all-cause 28-day mortality among COVID-19 outpatients during the Delta variant phase.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the National Center for Advancing Translational Sciences of the National Institutes of Health [grant numbers UL1TR002525, UL1TR002535-03S3 and UL1TR002535-04S2].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Colorado Multiple Institutional Review Board approved the study with a waiver of informed consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors